ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO573

Sarcopenia with Central Obesity Is Associated with an Increased Risk of All-Cause Mortality in Maintenance Hemodialysis Patients

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Song, Qirong, The Third Affiliated Hospital of Southern Medical University, Guangzhou City, China
  • Fu, Sha, The Third Affiliated Hospital of Southern Medical University, Guangzhou City, China
  • Chen, Junzhe, The Third Affiliated Hospital of Southern Medical University, Guangzhou City, China
  • Wang, Xiaohong, The Third Affiliated Hospital of Southern Medical University, Guangzhou City, China
  • Luo, Yuxin, The Third Affiliated Hospital of Southern Medical University, Guangzhou City, China
  • Liu, Aiqun, The Third Affiliated Hospital of Southern Medical University, Guangzhou City, China
  • Tang, Ying, The Third Affiliated Hospital of Southern Medical University, Guangzhou City, China

Group or Team Name

  • Nephrology Dept.
Background

Sarcopenia, a common condition found in maintenance dialysis (MHD) patients, is known to be linked to higher rates of illness and death. Several studies have indicated that central obesity can predict cardiovascular mortality in MHD patients. However, there is a knowledge gap regarding the impact of sarcopenia with central obesity on the survival of MHD patients.

Methods

This retrospective, observational, cohort study enrolled MHD patients on Sept 1-31, 2022. The Asian Working Group for Sarcopenia criteria and the waist hip rate (WHR) were used to diagnose sarcopenia with central obesity. Additionally, demographic, body composition, clinical laboratory and body composition by bioimpedance were collected.The primary outcome is all-cause mortality with MHD patient .

Results

A total of 59 MHD patients were included in this study, specifically, the prevalence of sarcopenia was 44.1% and the prevalence of sarcopenia with central obesity was found to be 49.2%. Over a median follow-up period of 214 days, a total of 5( 8.5% ) deaths occurred. Univariate Cox regression analyses revealed several factors associated with an increased risk of mortality, including age (HR: 0.055; p=0.098), 5-time chair stand test (HR: 0.044; p=0.029),and severe sarcopenia with central obesity (HR: 2.651; p<0.001). However, in the multivariate analysis, only severe sarcopenia with central obesity remained independently associated with all-cause mortality (HR: 2.734; p=0.015), indicating that severe sarcopenia with central obesity was linked to an increased risk of all-cause mortality in MHD patients.

Conclusion

It is crucial to consider the presence of central obesity when evaluating the correlation between sarcopenia and adverse outcomes in individuals undergoing dialysis.